JYNNEOS vaccine coverage by jurisdiction

JYNNEOS vaccine (the vaccine used in the current mpox outbreak) is effective at preventing mpox among people at risk of mpox. According to MMWR, JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox \u2014 United States, May 22, 2022\u2013January 31, 2023, although approximately 1.2 million vaccine doses have been administered, only 23% of the population at risk has been fully vaccinated nationally. Vaccine coverage varies widely between jurisdictions. Reasons for coverage variability could include lower vaccine accessibility and awareness, fewer vaccine providers, lower vaccine confidence and demand, and concern about stigma.To prevent new cases of mpox and future outbreaks, public health agencies and their partners are strongly encouraged to continue to improve vaccine equity and vaccine coverage among those at risk for mpox and increase the number of people fully vaccinated especially among those overly represented communities of Black and Hispanic or Latino men.Vaccine coverage estimates shown in the figure and table below cover May 22, 2022\u2013April 25, 2023 based on data reported to CDC as of April 25, at 4:00 AM.Beginning March 30, 2023, the data will be updated monthly